Literature DB >> 22045243

The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Colin A Hutchison1, Vecihi Batuman, Judith Behrens, Frank Bridoux, Christophe Sirac, Angela Dispenzieri, Guillermo A Herrera, Helen Lachmann, Paul W Sanders.   

Abstract

Renal failure remains a principal cause of morbidity for patients with multiple myeloma. Once reversible factors such as hypercalcemia have been corrected, the most common cause of severe renal failure in these patients is a tubulointerstitial pathology that results from the very high circulating concentrations of monoclonal immunoglobulin free light chains. These endogenous proteins can result in isolated proximal tubule cell cytotoxicity, tubulointerstitial nephritis and cast nephropathy (myeloma kidney). Less frequently, high levels of free light chains can lead to immunoglobulin light chain amyloidosis and light chain deposition disease, although these conditions are usually associated with insidious progression of renal failure rather than acute kidney injury. Unless there is rapid intervention, progressive and irreversible damage occurs, particularly interstitial fibrosis and tubular atrophy. Despite advances in our understanding of the pathogenesis of these processes there has been a gap in translating these achievements into improved patient outcomes. The International Kidney and Monoclonal Gammopathy Research Group was formed to address this need. In this Review, we discuss the mechanisms of disease and diagnostic approaches to patients with acute kidney injury complicating multiple myeloma.

Entities:  

Mesh:

Year:  2011        PMID: 22045243      PMCID: PMC3375610          DOI: 10.1038/nrneph.2011.168

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  103 in total

1.  Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein.

Authors:  Z Q Huang; P W Sanders
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease.

Authors:  S Déret; J Chomilier; D B Huang; J L Preud'homme; F J Stevens; P Aucouturier
Journal:  Protein Eng       Date:  1997-10

3.  Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells.

Authors:  V Batuman; S Guan
Journal:  Am J Physiol       Date:  1997-04

4.  Myeloma light chains are ligands for cubilin (gp280).

Authors:  V Batuman; P J Verroust; G L Navar; J H Kaysen; F O Goda; W C Campbell; E Simon; F Pontillon; M Lyles; J Bruno; T G Hammond
Journal:  Am J Physiol       Date:  1998-08

5.  Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model.

Authors:  A A Khamlichi; A Rocca; G Touchard; P Aucouturier; J L Preud'homme; M Cogné
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

6.  Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy.

Authors:  Z Q Huang; P W Sanders
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

7.  Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies.

Authors:  J J Montseny; D Kleinknecht; A Meyrier; P Vanhille; P Simon; A Pruna; D Eladari
Journal:  Nephrol Dial Transplant       Date:  1998-06       Impact factor: 5.992

8.  Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins.

Authors:  P W Stevens; R Raffen; D K Hanson; Y L Deng; M Berrios-Hammond; F A Westholm; C Murphy; M Eulitz; R Wetzel; A Solomon
Journal:  Protein Sci       Date:  1995-03       Impact factor: 6.725

9.  Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome.

Authors:  A Rocca; A A Khamlichi; G Touchard; B Mougenot; P Ronco; L Denoroy; S Deret; J L Preud'homme; P Aucouturier; M Cogné
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

10.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

Authors:  J Bladé; P Fernández-Llama; F Bosch; J Montolíu; X M Lens; S Montoto; A Cases; A Darnell; C Rozman; E Montserrat
Journal:  Arch Intern Med       Date:  1998-09-28
View more
  63 in total

1.  Crystalline cast nephropathy in a patient with IgD lambda myeloma.

Authors:  Satoshi Kumakura; Izaya Nakaya; Tsutomu Sakuma; Hiroshi Sato; Jun Soma
Journal:  Clin Exp Nephrol       Date:  2015-10-29       Impact factor: 2.801

Review 2.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

3.  Noninvasive assessment of corneal alterations associated with monoclonal gammopathy.

Authors:  Michiko Ichii; Shizuka Koh; Sayo Maeno; Caleb Busch; Yoshinori Oie; Tetsuo Maeda; Hirohiko Shibayama; Kohji Nishida; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2019-05-20       Impact factor: 2.490

Review 4.  Diagnostic work-up and specific causes of acute kidney injury.

Authors:  Michael Darmon; Marlies Ostermann; Jorge Cerda; Meletios A Dimopoulos; Lui Forni; Eric Hoste; Matthieu Legrand; Nicolas Lerolle; Eric Rondeau; Antoine Schneider; Bertrand Souweine; Miet Schetz
Journal:  Intensive Care Med       Date:  2017-04-25       Impact factor: 17.440

Review 5.  Kidney diseases associated with haematological cancers.

Authors:  Anirban Ganguli; Deirdre Sawinski; Jeffrey S Berns
Journal:  Nat Rev Nephrol       Date:  2015-06-02       Impact factor: 28.314

6.  Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.

Authors:  Mayuko Kawabe; Izumi Yamamoto; Ai Katsuma; Naomi Hayashi; Yo Komatsuzaki; Yasuyuki Nakada; Akihiro Shimizu; Yudo Tanno; Ichiro Ohkido; Nobuo Tsuboi; Kazuhito Suzuki; Takaki Shimada; Yoji Ogasawara; Katsuki Sugiyama; Keisuke Aiba; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2016-08-11

Review 7.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

Review 8.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

9.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

10.  Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome.

Authors:  Alessandro Luciani; Christophe Sirac; Sara Terryn; Vincent Javaugue; Jenny Ann Prange; Sébastien Bender; Amélie Bonaud; Michel Cogné; Pierre Aucouturier; Pierre Ronco; Frank Bridoux; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.